安科生物：目前生长激素市场竞争较激烈 但总体价格体系较为稳定

Core Viewpoint - Anke Bio (300009) reported that the growth hormone new patient enrollment is expected to maintain year-on-year growth in the first half of 2025, with the revenue share of water injections exceeding 40% of the total growth hormone product revenue [1] Group 1: Company Performance - The revenue from growth hormones is projected to remain stable compared to the same period last year due to less than ideal new patient enrollment in the second half of 2024 [1] - The company aims to achieve a recovery growth target by continuing to promote academic work related to growth hormones, leveraging the year-on-year growth in new patient enrollment in the first half of 2025 [1] Group 2: Market Conditions - The growth hormone market is experiencing intense competition; however, the overall pricing system remains relatively stable [1]